RADIOTHERAPY FOR EPIDERMOID CARCINOMA OF THE ANUS: THIRTY YEARS' EXPERIENCE

被引:36
作者
Myerson, Robert J. [1 ]
Outlaw, Elesyia D. [1 ]
Chang, Albert [1 ]
Birnbaum, Elisa H. [2 ]
Fleshman, James W. [2 ]
Grigsby, Perry W. [1 ]
Kodner, Ira J. [2 ]
Malayapa, Robert S. [2 ]
Mutch, Matthew G. [2 ]
Parikh, Parag [1 ]
Picus, Joel [3 ]
Tan, Benjamin R. [3 ]
机构
[1] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Sect Colorectal Surg, Dept Surg, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Dept Med, Div Med Oncol, St Louis, MO 63110 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2009年 / 75卷 / 02期
关键词
Anal cancer; Chemoradiotherapy; Normal tissue complications; MODULATED RADIATION-THERAPY; SQUAMOUS-CELL CARCINOMA; ANAL CANCER; RANDOMIZED-TRIAL; FDG-PET/CT; CHEMOTHERAPY; MITOMYCIN; CHEMORADIATION; 5-FLUOROURACIL; FLUOROURACIL;
D O I
10.1016/j.ijrobp.2008.11.047
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the factors associated with disease control and morbidity after radiotherapy for anal carcinoma. Methods and Materials: Between 1975 and 2005, 194 patients with localized epidermoid anal carcinoma underwent radiotherapy. Treatment evolved from radiotherapy with or without surgery, to preoperative chemoradiotherapy, to definitive chemoradiotherapy (CRT). The radiotherapy techniques also evolved. Results: With a median follow-up of 61 months, 57 patients had persistence or recurrence, 9 of whom were successfully salvaged, resulting in 146 (75%) ultimately free of disease (UNED). Univariate analysis for UNED survival showed a strong association with the T and N stage (5-year UNED rate, 88.5% +/- 3.4% for those with StageT1-T2N0; 70.1% +/- 4.2% for Stage T3N0; and 52.7% +/- 6.6% for Stage III;p > .001) and mobility on palpation (5-year UNED rate, 89.2% +/- 4.6% for those with mobile tumors vs. 59.3% +/- 6.1% for those with tethered/fixed tumor; p > .001). No association was found with gender, age, preoperative vs. definitive CRT, or human immunodeficiency virus status. The 20 human immunodeficiency virus+ patients all received CRT. The radiotherapy factors associated with Grade 3 or greater late morbidity included anorectal morbidity with tumor dose (29% with a dose >= 55 Gy vs. 9% otherwise), small bowel injury with technique (9% with anteroposterior-posteroanterior supine vs. 0.7% with multiple fields prone), and bone injury with femoral head dose (9% with a dose of >= 44 Gy vs. 0.7% otherwise). Of the 194 patients, 56 had 68 additional malignancies, mainly either antedating the anal cancer or outside the radiation fields. Conclusion: Our results have confirmed that CRT is an effective approach. Patients with human immunodeficiency virus can be treated with CRT. Tumor mobility significantly predicts the outcome; the implications for management are discussed. We also discuss the treatment planning implications of the late morbidity findings. The substantial incidence of additional malignancies underscores the importance of full oncologic screening during follow-up. (C) 2009 Elsevier Inc.
引用
收藏
页码:428 / 435
页数:8
相关论文
共 31 条
[1]   Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal - A randomized controlled trial [J].
Ajani, Jaffer A. ;
Winter, Kathryn A. ;
Gunderson, Leonard L. ;
Pedersen, John ;
Benson, Al B., III ;
Thomas, Charles R., Jr. ;
Mayer, Robert J. ;
Haddock, Michael G. ;
Rich, Tyvin A. ;
Willett, Christopher .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (16) :1914-1921
[2]  
[Anonymous], 2002, AJCC CANC STAG MAN
[3]  
Arnott SJ, 1996, LANCET, V348, P1049
[4]   Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups [J].
Bartelink, H ;
Roelofsen, F ;
Eschwege, F ;
Rougier, P ;
Bosset, JF ;
Gonzalez, DG ;
Peiffert, D ;
vanGlabbeke, M ;
Pierart, M .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :2040-2049
[5]   Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: Dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes [J].
Chen, YJ ;
Liu, A ;
Tsai, PT ;
Vora, NL ;
Pezner, RD ;
Schultheiss, TE ;
Wong, JYC .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (01) :274-281
[6]   Human immunodeficiency virus-associated squamous cell cancer of the anus: Epidemiology and outcomes in the highly active Antiretroviral therapy era [J].
Chiao, Elizabeth Y. ;
Giordano, Thomas P. ;
Richardson, Peter ;
El-Serag, Hashem B. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :474-479
[7]   FDG-PET/CT in the evaluation of anal carcinoma [J].
Cotter, Shane E. ;
Grigsby, Perry W. ;
Siegel, Barry A. ;
Dehdashti, Farrokh ;
Malyapa, Robert S. ;
Fleshman, James W. ;
Birnbaum, Elisa H. ;
Wang, Xia ;
Abbey, Elliot ;
Tan, Benjamin ;
Kodner, Ira J. ;
Hunt, Steven R. ;
Lowney, Jennifer K. ;
Mutch, Matthew G. ;
Dietz, David W. ;
Myerson, Robert J. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (03) :720-725
[8]  
COX DR, 1972, J R STAT SOC B, V34, P187
[9]  
CUMMINGS BJ, 1982, CANCER TREAT REP, V66, P489
[10]   EPIDERMOID ANAL CANCER - TREATMENT BY RADIATION ALONE OR BY RADIATION AND 5-FLUOROURACIL WITH AND WITHOUT MITOMYCIN-C [J].
CUMMINGS, BJ ;
KEANE, TJ ;
OSULLIVAN, B ;
WONG, CS ;
CATTON, CN .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (05) :1115-1125